Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

The following table represents Evolent’s revenue disaggregated by line of business and product type (in thousands):


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Medicaid	$	217,512	$	193,018	$	435,626	$	381,142
Medicare	225,292		109,042		388,102		224,360
Commercial and other	209,716		142,268		325,038		322,475
Total	$	652,520	$	444,328	$	1,148,766	$	927,977

Performance Suite (1)	$	484,503	$	267,917	$	807,806	$	570,938
Specialty Technology and Services Suite	78,161		81,401		158,960		164,222
Administrative Services	47,989		55,880		97,576		113,071
Cases	41,867		39,130		84,424		79,746
Total	$	652,520	$	444,328	$	1,148,766	$	927,977

————————

(1)Performance Suite revenue related to our specialty care management solution was $484.5 million and $807.8 million for the three and six months ended June 30, 2026, respectively, and $252.4 million and $497.7 million for the three and six months ended June 30, 2025, respectively.

Schedule of Contract with Customer, Asset and Liability

The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):




	June 30, 2026		December 31, 2025
Short-term receivables (1)	$	448,585	$	307,423

Short-term deferred revenue	1,208		1,203
Long-term deferred revenue	—		110

————————

(1)Excludes pharmacy rebate receivable and pharmacy claims receivable.

Changes in deferred revenue the six months ended June 30, 2026 are as follows (in thousands):


Deferred revenue
Balance as of beginning-of-period	$	1,313
Reclassification to revenue, as a result of performance obligations satisfied	(696)
Cash received in advance of satisfaction of performance obligations	591
Balance as of end of period	$	1,208